This session spotlighted Harmony-HHT, a global Phase 1/2 clinical trial recently initiated in the United States by Atavistik Bio. ATV-1601 is a novel oral investigational therapy under development in the Harmony-HHT Study.

In this webinar, Dr. Hanny Al-Samkari (Director of the Massachusetts General Brigham HHT CoE) and Dr. Susan Pandya (Chief Medical Officer of Atavistik Bio) introduced ATV-1601, shared key data supporting ATV-1601’s therapeutic potential, and provided an overview of the Harmony-HHT trial. The overview of Harmony-HHT included a discussion of how patient feedback was instrumental in designing the trial, details on who is eligible to participate in this exciting new study, and how to access participating centers.